Drugs / CPA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04920617 | Jun 2021 → Oct 2024 overdue | diffuse large B-cell lymphoma | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04920617 ↗ |
| Route | Oral | “intermittent oral CPA at a dose of 50 mg twice a day (BID)” NCT04920617 ↗ |